SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

SGLT2 inhibitors more cardioprotective in older versus younger people despite smaller reduction in HbA1c with older age ...

Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD exacerbation in adults with the disease and type 2 diabetes, researchers ...

Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks ...

Blockages in coronary arteries cause sudden heart attacks, leading to heart muscle damage. In contrast, heart failure is a ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

A recent study from the University of Hong Kong suggests that a newer type of diabetes drug, called sodium-glucose cotransporter 2 inhibitors (SGLT2i), may help protect the kidneys and lungs in people ...